At the crossroads of two of the world's most burdensome chronic conditions, a large observational study has surfaced a quietly remarkable signal: people with type 2 diabetes who take GLP-1 receptor agonists appear to develop tuberculosis at meaningfully lower rates than those on other glucose-lowering therapies. Drawing on health records spanning 153 million individuals, the finding suggests these medications may carry immunological benefits that extend well beyond blood sugar control. The discovery does not yet prove causation, but in a world where diabetes and tuberculosis frequently converg